History
Founded in 2011, Samabriva is a biotechnology company which has developed a disruptive platform (the “RHIZOBRIVA™” platform) from plant material enabling the production of biomolecules suitable for the pharmaceutical industry, as well as the cosmetics, agrochemicals and food industries
Using this platform, Samabriva focused its internal R&D program on the development of orphan drugs for the treatment of rare diseases, with a particular attention paid to the lysosomal storage disorders (« LSD »). Samabriva has built an independant business unit (the “NANOBRIVA™” platform) to gather these internal R&D programs.
RhizoBriva™
A greentech platform gathering the advantages of both plants and bioreactor-confined processes to produce complex molecules
NanoBriva ™
An innovative platform to develop innovative products in the rare diseases area